323 related articles for article (PubMed ID: 30719874)
1. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
[TBL] [Abstract][Full Text] [Related]
2. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
3. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
Meyer HJ; Strobel A; Wienke A; Surov A
Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
[TBL] [Abstract][Full Text] [Related]
5. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
6. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
[TBL] [Abstract][Full Text] [Related]
7. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
Meyer HJ; Wienke A; Surov A
Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
[TBL] [Abstract][Full Text] [Related]
8. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
[No Abstract] [Full Text] [Related]
9. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
[TBL] [Abstract][Full Text] [Related]
10. Comparing Western and Eastern criteria for sarcopenia and their association with survival in patients with pancreatic cancer.
Wu CH; Chang MC; Lyadov VK; Liang PC; Chen CM; Shih TT; Chang YT
Clin Nutr; 2019 Apr; 38(2):862-869. PubMed ID: 29503056
[TBL] [Abstract][Full Text] [Related]
11. CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas.
Surov A; Meyer HJ; Hinnerichs M; Ferraro V; Zeremski V; Mougiakakos D; Saalfeld S; Wienke A; Strobel A; Wolleschak D
Eur Radiol; 2024 Feb; 34(2):790-796. PubMed ID: 37178198
[TBL] [Abstract][Full Text] [Related]
12. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
Rier HN; Jager A; Sleijfer S; van Rosmalen J; Kock MCJM; Levin MD
Breast; 2017 Feb; 31():9-15. PubMed ID: 27810702
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
14. CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications.
Fang Z; Du F; Shang L; Liu J; Ren F; Liu Y; Wu H; Liu Y; Li P; Li L
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):317-324. PubMed ID: 33063547
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
Charette N; Vandeputte C; Ameye L; Bogaert CV; Krygier J; Guiot T; Deleporte A; Delaunoit T; Geboes K; Van Laethem JL; Peeters M; Demolin G; Holbrechts S; Flamen P; Paesmans M; Hendlisz A
BMC Cancer; 2019 Feb; 19(1):134. PubMed ID: 30744591
[TBL] [Abstract][Full Text] [Related]
16. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505.
Sohal DPS; Boutin RD; Lenchik L; Kim J; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Chang VT
J Gastrointest Surg; 2024 Mar; 28(3):232-235. PubMed ID: 38445914
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy.
Kurita Y; Kobayashi N; Tokuhisa M; Goto A; Kubota K; Endo I; Nakajima A; Ichikawa Y
Pancreatology; 2019 Jan; 19(1):127-135. PubMed ID: 30473464
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.
Meyer HJ; Wienke A; Surov A
Nutr Cancer; 2022; 74(10):3518-3526. PubMed ID: 35603926
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study.
Maddalena C; Ponsiglione A; Camera L; Santarpia L; Pasanisi F; Bruzzese D; Panico C; Fiore G; Camardella S; Caramia T; Farinaro A; De Placido S; Carlomagno C
World J Clin Oncol; 2021 May; 12(5):355-366. PubMed ID: 34131567
[TBL] [Abstract][Full Text] [Related]
20. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease.
Kang MK; Park JG; Lee HJ; Kim MC
J Gastroenterol Hepatol; 2019 Sep; 34(9):1633-1640. PubMed ID: 30667551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
